Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Lung Cancer (Amsterdam, Netherlands)|August 27, 2014
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancerCeline Pallaud, Martin Reck, Erzsebet Juhasz, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2012
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in studyGeorge R Blumenschein, Tudor Ciuleanu, Francisco Robert, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2014
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015)Tony Mok, Vera Gorbunova, Erzsebet Juhasz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung CancerSuresh S Ramalingam, Normand Blais, Julien Mazieres, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.Pageof 1